Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1357
mi
from
Hurst, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1357
mi
from
Hurst, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1826
mi
from
Plano, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1826
mi
from
Plano, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1269
mi
from
Tomball, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1269
mi
from
Tomball, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 125
mi
from
Abingdon, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 125
mi
from
Abingdon, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 117
mi
from
Lynchburg, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 117
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative site 031
mi
from
Norfolk, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative site 031
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 020
mi
from
Richmond, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 020
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1870
mi
from
Tacoma, WA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1870
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1177
mi
from
Vancouver,
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1177
mi
from
Vancouver,
Click here to add this to my saved trials
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated:  11/5/2015
Novartis Investigative Site
mi
from
Akron, OH
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated: 11/5/2015
Novartis Investigative Site
mi
from
Akron, OH
Click here to add this to my saved trials
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated:  11/5/2015
Novartis Investigational Site
mi
from
Charleston, SC
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated: 11/5/2015
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated:  11/5/2015
Novartis Investigative site
mi
from
Dallas, TX
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated: 11/5/2015
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated:  11/5/2015
Novartis Investigative Site
mi
from
Houston, TX
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated: 11/5/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated:  11/5/2015
Novartis Investigative Site
mi
from
Caba,
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.
Status: Enrolling
Updated: 11/5/2015
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
Comparator Trial Evaluating Microbiological Resistance and Clinical Efficacy in Patients Using Alternation Therapy of Inhaled Antibiotics
Status: Enrolling
Updated:  11/5/2015
Indiana University
mi
from
Indianapolis, IN
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
Comparator Trial Evaluating Microbiological Resistance and Clinical Efficacy in Patients Using Alternation Therapy of Inhaled Antibiotics
Status: Enrolling
Updated: 11/5/2015
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A
The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects
Status: Enrolling
Updated:  11/6/2015
Sleep Disorders Research Program Brigham and Women's Hospital
mi
from
Boston, MA
Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A
The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects
Status: Enrolling
Updated: 11/6/2015
Sleep Disorders Research Program Brigham and Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B
The Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity During Sleep in Patients With Obstructive Sleep Apnea - Study B
Status: Enrolling
Updated:  11/6/2015
Sleep Disorders Research Program Brigham and Women's Hospital
mi
from
Boston, MA
Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B
The Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity During Sleep in Patients With Obstructive Sleep Apnea - Study B
Status: Enrolling
Updated: 11/6/2015
Sleep Disorders Research Program Brigham and Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison of Asthma Programs for Schools
Comparison of Asthma Programs for Schools
Status: Enrolling
Updated:  11/6/2015
University of Texas at Austin
mi
from
Austin, TX
Comparison of Asthma Programs for Schools
Comparison of Asthma Programs for Schools
Status: Enrolling
Updated: 11/6/2015
University of Texas at Austin
mi
from
Austin, TX
Click here to add this to my saved trials
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction
Status: Enrolling
Updated:  11/9/2015
University of Medicine and Dentistry of New Jersey/ New Jersey Medical School
mi
from
Newark, NJ
Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction
Status: Enrolling
Updated: 11/9/2015
University of Medicine and Dentistry of New Jersey/ New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated:  11/10/2015
Children's Hospital Boston
mi
from
Boston, MA
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated: 11/10/2015
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated:  11/10/2015
Cardinal Glennon Children's Medical Center
mi
from
St. Louis, MO
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated: 11/10/2015
Cardinal Glennon Children's Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated:  11/10/2015
Montefiore Children's Hospital
mi
from
New York, NY
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated: 11/10/2015
Montefiore Children's Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated:  11/10/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated: 11/10/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated:  11/10/2015
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated: 11/10/2015
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated:  11/10/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Childhood Adenotonsillectomy Study for Children With OSAS
A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome
Status: Enrolling
Updated: 11/10/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Status: Enrolling
Updated:  11/10/2015
Thomason Hospital (Now University Medical Center)
mi
from
El Paso, TX
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)
Status: Enrolling
Updated: 11/10/2015
Thomason Hospital (Now University Medical Center)
mi
from
El Paso, TX
Click here to add this to my saved trials
Progesterone for the Treatment of Cocaine Dependence - 1
Interactions Between Progesterone and Cocaine in Women
Status: Enrolling
Updated:  11/16/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Progesterone for the Treatment of Cocaine Dependence - 1
Interactions Between Progesterone and Cocaine in Women
Status: Enrolling
Updated: 11/16/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Morgantown, WV
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Jasper, AL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Mobile, AL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Huntington Beach, CA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Los Angeles, CA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Clearwater, FL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Ormond Beach, FL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Lawrenceville, GA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Topeka, KA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Madisonville, KY
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Madisonville, KY
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Lafayette, LA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Lafayette, LA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
New Orleans, LA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
St. Louis, MO
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Charlotte, NC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Elizabeth City, NC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Elizabeth City, NC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Cincinnati, OH
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Medford, OR
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Beaver, PA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Beaver, PA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Easley, SC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Spartanburg, SC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Comparison of Absorption of Vitamin D in Cystic Fibrosis
Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil
Status: Enrolling
Updated:  11/19/2015
Emory University Hospital
mi
from
Atlanta, GA
Comparison of Absorption of Vitamin D in Cystic Fibrosis
Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil
Status: Enrolling
Updated: 11/19/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials